Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Sep 19;93(6):613-9.
doi: 10.1038/sj.bjc.6602774.

Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide

J B Bartlett  1 , A Tozer, D Stirling, J B Zeldis
Affiliations
Review

Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide

J B Bartlett et al. Br J Cancer. .

Abstract

Thalidomide is effective in the treatment of multiple myeloma. The immunomodulatory drug and thalidomide analogue lenalidomide is currently in late stage clinical development for MDS and multiple myeloma. This minireview highlights the course of initial and ongoing lenalidomide clinical development in oncology with reference to earlier thalidomide studies.

PubMed Disclaimer

References

    1. Bartlett JB, Dredge K, Dalgleish AG (2004a) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4: 314–322 - PubMed
    1. Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI, Zeldis J, Dalgleish AG (2004b) Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 90(5): 955–961 - PMC - PubMed
    1. Baz R, Marchant K, Yiannaki EO, Platt L, Brand C, Tso E, Hussein MA (2004) Aspirin decreases the thrombotic complications (DVT) of liposomal doxorubicin, vincristine, decreased frequency dexamethasone and thalidomide (DVd-T) treatment of multiple myeloma (MM). Blood 104(11): 658a–659a, (abstract #2397)
    1. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD (2004) Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22(13): 2532–2539 - PubMed
    1. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98: 210–216 - PubMed

MeSH terms